The genetic background and vitamin D supplementation can affect irisin levels in Prader-Willi syndrome.
Irisin
Prader–Willi syndrome
Vitamin D supplementation
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
31
12
2020
accepted:
10
02
2021
pubmed:
4
3
2021
medline:
19
1
2022
entrez:
3
3
2021
Statut:
ppublish
Résumé
Prader-Willi syndrome (PWS) is associated to distinctive clinical symptoms, including obesity, cognitive and behavioral disorders, and bone impairment. Irisin is a myokine that acts on several target organs including brain adipose tissue and bone. The present study was finalized to explore circulating levels of irisin in children and adult PWS patients. Seventy-eight subjects with PWS, 26 children (15 females, mean age 9.48 ± 3.6 years) and 52 adults (30 females, mean age 30.6 ± 10.7) were enrolled. Irisin serum levels were measured in patients and controls. Its levels were related with anthropometric and metabolic parameters, cognitive performance and bone mineral density either in pediatric or adult PWS. Multiple regression analysis was also performed. Irisin serum levels in PWS patients did not show different compared with controls. A more in-depth analysis showed that both pediatric and adult PWS with DEL15 displayed significantly reduced irisin levels compared to controls. Otherwise, no differences in irisin concentration were found in UPD15 patients with respect to controls. Our study revealed that in pediatric PWS the 25(OH) vitamin-D levels affected irisin serum concentration. Indeed, patients who were not supplemented with vitamin D showed lower irisin levels than controls and patients performing the supplementation. Multiple regression analysis showed that irisin levels in pediatric and adult PWS were predicted by the genetic background and 25(OH)-vitamin D levels, whereas in a group of 29 adult PWS also by intelligent quotient. We demonstrated the possible role of genetic background and vitamin-D supplementation on irisin serum levels in PWS patients.
Sections du résumé
BACKGROUND
BACKGROUND
Prader-Willi syndrome (PWS) is associated to distinctive clinical symptoms, including obesity, cognitive and behavioral disorders, and bone impairment. Irisin is a myokine that acts on several target organs including brain adipose tissue and bone. The present study was finalized to explore circulating levels of irisin in children and adult PWS patients.
METHODS
METHODS
Seventy-eight subjects with PWS, 26 children (15 females, mean age 9.48 ± 3.6 years) and 52 adults (30 females, mean age 30.6 ± 10.7) were enrolled. Irisin serum levels were measured in patients and controls. Its levels were related with anthropometric and metabolic parameters, cognitive performance and bone mineral density either in pediatric or adult PWS. Multiple regression analysis was also performed.
RESULTS
RESULTS
Irisin serum levels in PWS patients did not show different compared with controls. A more in-depth analysis showed that both pediatric and adult PWS with DEL15 displayed significantly reduced irisin levels compared to controls. Otherwise, no differences in irisin concentration were found in UPD15 patients with respect to controls. Our study revealed that in pediatric PWS the 25(OH) vitamin-D levels affected irisin serum concentration. Indeed, patients who were not supplemented with vitamin D showed lower irisin levels than controls and patients performing the supplementation. Multiple regression analysis showed that irisin levels in pediatric and adult PWS were predicted by the genetic background and 25(OH)-vitamin D levels, whereas in a group of 29 adult PWS also by intelligent quotient.
CONCLUSION
CONCLUSIONS
We demonstrated the possible role of genetic background and vitamin-D supplementation on irisin serum levels in PWS patients.
Identifiants
pubmed: 33656700
doi: 10.1007/s40618-021-01533-4
pii: 10.1007/s40618-021-01533-4
pmc: PMC8421289
doi:
Substances chimiques
Biomarkers
0
FNDC5 protein, human
0
Fibronectins
0
Vitamins
0
Vitamin D
1406-16-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2261-2271Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
J Clin Endocrinol Metab. 2009 Oct;94(10):3763-71
pubmed: 19622627
Nature. 2012 Jan 11;481(7382):463-8
pubmed: 22237023
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3088-3096
pubmed: 30759249
Obesity (Silver Spring). 2012 Sep;20(9):1866-70
pubmed: 22193922
BMJ. 2000 May 6;320(7244):1240-3
pubmed: 10797032
Int J Endocrinol. 2014;2014:261545
pubmed: 25276128
Clin Endocrinol (Oxf). 2015 Apr;82(4):615-9
pubmed: 25400208
PLoS One. 2015 Sep 03;10(9):e0136864
pubmed: 26334732
Arch Clin Neuropsychol. 1997;12(2):97-109
pubmed: 14588421
Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):12157-62
pubmed: 26374841
Calcif Tissue Int. 2018 Jun;102(6):635-643
pubmed: 29353451
J Pediatr. 2001 Nov;139(5):708-14
pubmed: 11713451
Diabetes Metab Syndr Obes. 2018 Oct 04;11:579-593
pubmed: 30323638
Behav Neurosci. 2020 Jun;134(3):233-247
pubmed: 32437197
J Biol Regul Homeost Agents. ;31(4 suppl 1):21-28
pubmed: 29181953
J Bone Miner Res. 1992 Feb;7(2):137-45
pubmed: 1570758
J Speech Disord. 1949 Dec;14(4):318-21
pubmed: 15397895
Am J Med Genet A. 2020 Jan;182(1):115-121
pubmed: 31692257
Pediatr Res. 2019 Mar;85(4):484-488
pubmed: 30683930
J Clin Endocrinol Metab. 2002 Aug;87(8):3590-7
pubmed: 12161480
Adv Data. 2000 Jun 8;(314):1-27
pubmed: 11183293
Int J Obes (Lond). 2014 Sep;38(9):1234-40
pubmed: 24406482
Sci Rep. 2020 Jan 23;10(1):1020
pubmed: 31974460
Eur J Endocrinol. 2005 Aug;153(2):257-64
pubmed: 16061832
Am J Med Genet. 2001 Oct 15;103(3):216-22
pubmed: 11745993
Nat Med. 2019 Jan;25(1):165-175
pubmed: 30617325
Int J Pediatr Endocrinol. 2018;2018:1
pubmed: 29371863
J Med Genet. 2019 Mar;56(3):149-153
pubmed: 29730598
BMC Fam Pract. 2020 Feb 7;21(1):26
pubmed: 32033527
J Clin Endocrinol Metab. 2019 Mar 1;104(3):801-808
pubmed: 30418584
J Bone Miner Res. 2017 Jan;32(1):172-180
pubmed: 27490028
Sci Rep. 2017 Jun 6;7(1):2811
pubmed: 28588307
J Endocrinol Invest. 2011 Apr;34(4):e86-91
pubmed: 20855933
Pediatr Diabetes. 2003 Sep;4(3):119-25
pubmed: 14655269
J Clin Endocrinol Metab. 2012 Feb;97(2):E275-81
pubmed: 22162467
Pediatrics. 1993 Feb;91(2):398-402
pubmed: 8424017
J Endocrinol Invest. 2015 Dec;38(12):1249-63
pubmed: 26062517
Diabetes Res Clin Pract. 2018 Jul;141:10-17
pubmed: 29679630
Prog Cardiovasc Dis. 2019 Mar - Apr;62(2):172-178
pubmed: 30844383
Arch Dis Child. 1976 Mar;51(3):170-9
pubmed: 952550
PLoS One. 2014 Jun 13;9(6):e100218
pubmed: 24926783
J Alzheimers Dis. 2017;59(3):1097-1111
pubmed: 28731451
PLoS One. 2013 Apr 11;8(4):e60563
pubmed: 23593248
J Pediatr. 2004 May;144(5):614-9
pubmed: 15126995